EAACI Helsinki 2017

This symposium concerns the role of bilastine in the treatment of allergic rhinitis and urticaria and is sponsored by FAES FARMA.

Allergic diseases are amongst the most common chronic diseases worldwide and are the most common such disease in Europe. Their global prevalence continues to increase, especially in low- and middle-income countries, including the Asia-Pacific region

In addition to the impact and incidence of allergies in adults, there is particular concern regarding the impact of allergic rhinitis and urticaria in the paediatric population.

This symposium is intended to share the latest clinical evidence concerning development of the new H1 antihistamine bilastine for the treatment of allergies in adults and children.

Only registered health professionals are allowed to see the report